| Literature DB >> 16548448 |
Bertram Pitt1, Sanjay Rajagopalan.
Abstract
Many patients with heart failure should receive an aldosterone receptor antagonist, ie, either spironolactone (Aldactone) or the newer agent eplerenone (Inspra)--in addition to an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) or both, and a beta-blocker. We review the evidence and indications.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16548448 DOI： 10.3949/ccjm.73.3.257
Source DB: PubMed Journal: Cleve Clin J Med ISSN： 0891-1150 Impact factor: 2.321